Drug intelligence / Profile preview

HCW11-027

Development stage: Preclinical
Lead developer: HCW Biologics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

HCW11-027 is a research-stage immunotherapeutic biologic developed by HCW Biologics using its proprietary T-cell Receptor Beta Chain (TRBC) platform. The TRBC platform is designed to create multi-functional molecules that activate immune responses while specifically targeting cancerous or infected cells. HCW11-027 is part of a pipeline of over 50 molecules and is intended for potential applications in oncology, autoimmune diseases, and quality-of-life conditions. As of mid-2025, the compound is undergoing preclinical evaluation, though its specific biological targets and primary indications have not been publicly disclosed.

Other names: HCW11-027HCW-11-027HCW 11-027

Beyond the preview

Go deeper on HCW11-027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCW11-027.

Explore the full profile